(Reuters) - The U.S. Food and Drug Administration said on Thursday it approved an Eli Lilly and Co drug to treat advanced breast cancer that has progressed following prior treatment.
The drug, abemaciclib, which will be sold under the brand name Verzenio, will carry a list price before any discounts or rebates of about $10,948 per month, Lilly said.
Verzenio belongs to a newer class of oral medicines called CDK 4/6 inhibitors that block cancer cells’ ability to divide and proliferate. It will compete with Pfizer Inc’s Ibrance and Kisqali from Novartis AG .
“Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously treated with endocrine therapy and chemotherapy,” Richard Pazdur, the FDA’s head of oncology drug evaluation, said in a statement.
Lilly said Verzenio will be available in the United States by the end of October. Under a special savings card program, the company said eligible commercially insured patients may obtain the first three months of therapy free, then pay no more than $10 per month for up to 12 months.
Lilly, in an emailed statement, said it will work with insurers, health systems and providers to ensure patient access to the treatment.
In a pivotal clinical trial, abemaciclib when added to standard therapy reduced the risk of disease progression by 46 percent. It also led to significant tumor shrinkage in 59 percent of patients compared with 44 percent of those who received endocrine drugs alone in the study.
It was approved for adults who have hormone receptor HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy that alters a patient’s hormones, the FDA said.
An estimated 252,710 women will be diagnosed with breast cancer this year, and 40,610 will die of the disease, according to the National Institutes of Health. About 72 percent of patients with breast cancer have tumors that are HR-positive and HER2-negative.
Eli Lilly shares closed up 35 cents, or 0.4 percent, at $85.00 on the New York Stock Exchange.
Reporting by Bill Berkrot; Editing by Tom Brown, Jonathan Oatis and David Gregorio
Our Standards: The Thomson Reuters Trust Principles.